Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2018-12, Vol.126, p.1-8
• Main Authors: Wu, Yi-Long, Lee, Victor, Liam, Chong-Kin, Lu, Shun, Park, Keunchil, Srimuninnimit, Vichien, Wang, Jie, Zhou, Caicun, Appius, Anita, Button, Peter, Hooper, Gregory, Palma, John F., Schulze, Katja, Scudder, Sidney, Shames, David S., Yin, Anny-Yue, Zhang, Guili, Mok, Tony
• Format: Article
• Language: English
• Subjects: Blood-based testing; Cobas assay; EGFR mutation; Erlotinib
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2018.10.004

•The cobas® v2 EGFR mutation blood test has high specificity and good sensitivity.•Sensitivity of the test was greatest in patients with larger baseline tumor burden.•Prolonged survival was seen with discordant (tissue+/plasma-) EGFR mutation status.•EGFR mutation testing in blood is a convenient, non-invasive, diagnostic option.•These results inform the clinical utility of the cobas® v2 EGFR mutation test. Patients with advanced non-small-cell lung cancer (NSCLC) with an adenocarcinoma component are recommended to undergo epidermal growth factor receptor (EGFR) mutation testing when being considered for EGFR targeted therapy. We conducted an exploratory analysis to inform the clinical utility of EGFR mutation testing in blood cell-free DNA using the cobas®EGFR Mutation Test v2. Two EGFR mutation tests, a tissue-based assay (cobas® v1) and a tissue- and blood-based assay (cobas® v2) were used to analyze matched biopsy and blood samples (897 paired samples) from three Asian studies of first-line erlotinib with similar intent-to-treat populations. ENSURE was a phase III comparison of erlotinib and gemcitabine/platinum, FASTACT-2 was a phase III study of gemcitabine/platinum plus erlotinib or placebo, and ASPIRATION was a single-arm phase II study of erlotinib. Agreement statistics were evaluated, based on sensitivity and specificity between the two assays in subgroups of patients with increasing tumor burden. Patients with discordant EGFR (tissue+/plasma-) mutation status achieved longer progression-free and overall survival than those with concordant (tissue+/plasma+) mutation status. Tumor burden was significantly greater in patients with concordant versus discordant mutations. Pooled analyses of data from the three studies showed a sensitivity of 72.1% (95% confidence interval [CI] 67.8–76.1) and a specificity of 97.9% (95% CI 96.0–99.0) for blood-based testing; sensitivity was greatest in patients with larger baseline tumors. Blood-based EGFR mutation testing demonstrated high specificity and good sensitivity, and offers a convenient and easily accessible diagnostic method to complement tissue-based tests. Patients with a discordant mutation status in plasma and tissue, had improved survival outcomes compared with those with a concordant mutation status, which may be due to their lower tumor burden. These data help to inform the clinical utility of this blood-based assay for the detection of EGFR mutations.